Form 4: Sana Biotechnology Director Alise Reicin Granted 80,000 Stock Options

Sana Biotechnology, Inc. (SANA) Director Alise Reicin has been granted 80,000 stock options, aligning her interests with shareholder value.

Summary

• Alise Reicin, a Director of Sana Biotechnology, Inc. (SANA), acquired 80,000 stock options.
• The transaction date for the option grant was June 5, 2025.
• Each option has an exercise price of $2.55.
• The options will vest and become exercisable as to 100% of the underlying shares on the earlier of June 5, 2026, or immediately prior to Sana's 2026 annual meeting of stockholders.
• Vesting is contingent upon Ms. Reicin providing continuous service to Sana through the vesting date.
• The options have an expiration date of June 4, 2035.
• Following this transaction, Ms. Reicin beneficially owns 80,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally viewed positively as it aligns the director's financial interests with the long-term performance of the company's stock, indicating confidence from an insider.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the options gain value if the company's stock price increases.
• The acquisition of options by an insider can signal confidence in the company's future prospects.

Industry Context

This Form 4 filing reports a standard equity compensation grant to a director, a common practice across industries, including biotechnology, to incentivize long-term performance and align interests with shareholders. It does not provide broader industry trends or competitive insights.

Related Party Transactions

• The transaction involves the grant of stock options to Alise Reicin, a director of Sana Biotechnology, Inc., which is a standard form of compensation for a related party.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial incentives with shareholder value creation, as the options become more valuable if the stock price increases.

Next Steps

• The options will vest on the earlier of June 5, 2026, or immediately prior to the 2026 annual meeting of stockholders, provided continuous service.

Key Dates

Keywords

Sana Biotechnology, SANA, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Beneficial Ownership